Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a ...

Researchers developed an assay kit for TAT, then conducted a retrospective analysis to determine its ability to predict VTE in patients with cervical cancer.

We recently published an article titled These 10 Firms Led This Week’s Rally. In this article, we are going to take a look at ...

Irvine-based Inari Medical Inc. will be acquired by Stryker Corp. for $4.8 billion. The boards of directors of both companies ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Stryker is in advanced talks to acquire Inari Medical to enhance offerings for venous disease treatments. The deal, if successful, will strengthen Stryker's position in the medical device sector.

Stryker is in advanced discussions to acquire Inari Medical, a company producing devices for venous diseases. If successful, the acquisition, valued at nearly $3 billion, would enhance Stryker's ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

Acquisition strengthens Stryker’s position in the venous thromboembolism (VTE) treatment market,Expected to close by the end ...

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: ...